Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 11/20 | 0.73 |
| ▸ | HDAC1 | Q13547 | 16/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.63 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.63 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.63 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.63 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.63 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.62 |
| ▸ | CDK1 | P06493 | 1/20 | 0.62 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.62 |
| ▸ | CDK2 | P24941 | 1/20 | 0.62 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2412138 | 0.85 | HDAC1 (0.66) | HDAC2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL6243828 | 0.84 | HDAC1 (0.76) | HDAC2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL15933349 | 0.84 | HDAC2 (1.00) | HDAC2HDAC1HDAC3HDAC4HDAC7 | |
| Hydrochloric Acid SCHEMBL1435432 | 0.83 | HDAC1 (0.74) | HDAC2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL2410081 | 0.83 | HDAC1 (0.78) | HDAC2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL29603842 | 0.82 | HDAC1 (0.76) | HDAC2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL675168 | 0.82 | HDAC1 (0.76) | HDAC2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL3943929 | 0.81 | HDAC2 (0.67) | HDAC2HDAC1HDAC3HDAC4HDAC7 | |
| Hydrochloric Acid SCHEMBL2418342 | 0.81 | HDAC1 (0.71) | HDAC2HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL8279058 | 0.81 | HDAC2 (0.67) | HDAC2HDAC1HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026239-B2 | Cell differentiation inducer | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-27 | — | — | US | disclosed |
| US-20100256201-A1 | CELL DIFFERENTIATION INDUCER | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-07 | — | — | US | disclosed |
| US-7687525-B2 | Cell differentiation inducer | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-30 | — | — | US | disclosed |
| US-RE40703-E1 | Cell differentiation inducer, benzamide compounds | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-04-28 | — | — | US | disclosed |
| US-20080188489-A1 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-08-07 | — | — | US | disclosed |
| US-7317028-B2 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-01-08 | — | — | US | disclosed |
| US-RE39754-E1 | Benzamide derivatives and pharmaceutical compositions containing same | SCHERING AG (DE) | 2007-07-31 | — | — | US | disclosed |
| EP-1738752-A1 | Pharmaceutical combinations comprising cis-retine acid | Schering Aktiengesellschaft (DE) | 2007-01-03 | — | — | EP | disclosed |
| EP-1641458-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-04-05 | — | — | EP | disclosed |
| US-20050054647-A1 | New pharmaceutical combination | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-03-10 | — | — | US | disclosed |
| US-6794392-B1 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-09-21 | — | — | US | disclosed |
| US-20040147569-A1 | Antitumor agents; autoimmune disease; skin disorders; anticancer agents | SCHERING AKTIENGESELLSCHAFT | 2004-07-29 | — | — | US | disclosed |
| WO-2004058234-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | disclosed |
| EP-1437346-A1 | Benzamide derivatives useful as cell differentiation inducers | Schering AG (DE) | 2004-07-14 | — | — | EP | disclosed |
| EP-0847992-B1 | Benzamide derivatives, useful as cell differentiation inducers | SCHERING AG (DE) | 2004-06-23 | — | — | EP | disclosed |
| US-6174905-B1 | AS CARCINOSTATIC AGENT TO A HEMATOLOGIC MALIGNANCY AND A SOLID CARCINOMA | MITSUI CHEMICALS, INC. (JP) | 2001-01-16 | — | — | US | disclosed |
| EP-0847992-A1 | Benzamide derivatives, useful as cell differentiation inducers | Mitsui Chemicals, Inc. (JP) | 1998-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188489-A1 | Cell differentiation inducer | MCL1, MYADM, MYD88 | HDAC2 170/4885HDAC1 150/4885HDAC3 618/4885 |
| US-20040147569-A1 | Antitumor agents; autoimmune disease; skin disorders; anticancer agents | MCL1, MYADM, PDCD1 | HDAC2 204/4885HDAC1 81/4885HDAC3 807/4885 |
| US-20100256201-A1 | CELL DIFFERENTIATION INDUCER | MCL1, MYADM, MYD88 | HDAC2 183/4885HDAC1 163/4885HDAC3 680/4885 |
| US-20050054647-A1 | New pharmaceutical combination | VEGFA, INHA, PGF | HDAC2 1101/4885HDAC1 976/4885HDAC3 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.